Apimeds Pharmaceuticals US, Inc. - APUS

Detailed investor-level table based on 13F positions.

Shareholders (13F)

Quarter: Q1 2026 · Compare: Q4 2025
13D/13G major owners: Ownership tab.
Methodology: Market value and % of portfolio use SEC reported VALUE ($000). For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received. Details.
Rows: 0
Investor History Status Shares held Market value ($000) % of portfolio Previous % Rank Change in shares % change in shares Source Date reported
Hemenway Trust Co LLC History No change 274,000 490 0.04% 0.03% 1 0 0.0% Q1 2026 May 07, 2026
VANGUARD CAPITAL MANAGEMENT LLC History New 95,929 171 0.0% 2 +95,929 New Q1 2026 May 15, 2026
VANGUARD GROUP INC History No change 58,992 96 0.0% 0.0% 3 0 0.0% Q4 2025 Jan 29, 2026
GEODE CAPITAL MANAGEMENT, LLC History Added to 40,051 71 0.0% 0.0% 4 +5,163 14.8% Q1 2026 May 15, 2026
VANGUARD FIDUCIARY TRUST CO History New 24,039 43 0.0% 5 +24,039 New Q1 2026 May 08, 2026
TWO SIGMA SECURITIES, LLC History New 10,550 18 0.0% 6 +10,550 New Q1 2026 May 15, 2026
UBS Group AG History Added to 4,187 7 0.0% 7 +3,605 619.42% Q1 2026 May 05, 2026
JANE STREET GROUP, LLC History Closed out 0 0 0.0% -27,188 -100.0% Q1 2026 May 12, 2026
BANK OF AMERICA CORP /DE/ History Closed out 0 0 -40 -100.0% Q1 2026 May 15, 2026
Tower Research Capital LLC (TRC) History Closed out 0 0 -10 -100.0% Q1 2026 May 15, 2026